Novo Nordisk A/s

Dgi Biotechnologies, Inc.

Lauge Schäffer

Jesper F Lau

Thomas Kruse

Patrick William Garibay

Thomas Kruse Hansen

Ingrid Pettersson

Jacob Kofoed

Kjeld Madsen

Henning Thøgersen

Jane Spetzler

Leif Hoejslet Christensen

Steffen Reedtz-Runge

Jakob Brandt

Florencio Zaragoza Dörwald

Per Hertz Hansen

Arthur J Blume

János Tibor Kodra

Renee Brissette

Kirsten Dahl

Renuka Pillutla

Søren Østergaard

Steffen Runge

Weiqing Cheng

Mark Ravera

Ku-Chuan Hsiao

Wlodek S Mandecki

Sören Östergaard

Amylin derivatives, pharmaceutical compositions containing such derivatives, as well as methods of treating diabetes and hyperglycaemia are disclosed.

Amylin derivatives

The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.

Glucagon-Like Peptide-1 derivatives and their pharmaceutical use

The present invention relates to novel amylin derivatives having a protracted action profile, to pharmaceutical compositions comprising these derivatives and to the use of the derivatives for the treatment of diseases related to obesity, diabetes and other metabolic disorders.

Growing community of inventors

Lyngby, Denmark

Lauge Schäffer